BioSpace News Archive

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors

Tauriga Sciences, Inc. announced that the United Kingdom’s top alternative well-being magazine, Natural Health Magazine, to feature Tauri-Gum™ in its March 2020 Edition.

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor for the treatment of facioscapulohumeral muscular dystrophy (FSHD)

InnerScope introduces a Dietary Hearing Supplement that supports both the Brain & Hearing Health for Americans age 50 and older who are buying the biggest slice of the very large brain-health dietary supplements market, which is expected to reach $5.8 billion in sales by 2023

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris (PV)

Pharmacosmos Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Monoferric® (ferric derisomaltose) injection 100 mg/mL

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, announced today that it has received approximately $1.45 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $1.56 per share.

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, will participate in the IMCAS World Congress, one of the largest European meetings of plastic and aesthetic surgeons, which will take place in Paris, France from January 30 - February 1, 2020.

VADovations, Inc., a company developing miniaturized cardiac assist pumps offering best-in-class blood handling properties, high performance and low cost, today announces an agreement to license intellectual property from Mayo Clinic for endovascular deployment of VADovations’ novel cardiac assist pump for long-term use in patients suffering with heart failure.